HeartBeam, Inc.
No SEC Form 4 filings for $BEAT in the last 30 days.
HeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001779372 0001779372 2026-07-31 2026-07-31 0001779372 us-gaap:CommonStockMember 2026-07-31 2026-07-31 0001779372 us-gaap:WarrantMember 2026-07-31 2026-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
HeartBeam Inc. (BEAT) said the U.S. Patent Office allowed a new patent covering acoustic sensing and thoracic impedance measurement for its cable-free ECG device. The company says the device can act as a digital stethoscope and monitor chest fluid buildup for heart failure management. BEAT shares were about $0.50, down 11.91%, near a 52-week low.
HeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001779372 0001779372 2026-06-18 2026-06-18 0001779372 us-gaap:CommonStockMember 2026-06-18 2026-06-18 0001779372 us-gaap:WarrantMember 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
Over the past 7 days, alphai's AI scored 1 news story mentioning BEAT (HeartBeam, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BEAT coverage spans financial news, corporate actions and technology.
The filing is primarily governance housekeeping. The only potentially market-relevant item is that the equity incentive plan share increase proposal was not approved.
Patent allowance strengthens HeartBeam’s IP moat around its cable-free ECG and digital stethoscope plus fluid-monitoring concept.
Leadership transition via strategic reorganization; near-term uncertainty around execution and governance, with interim alignment under founder/president.
The filing discloses executive compensation terms (2.8M RSUs) with performance milestones and change-in-control/termination-based vesting triggers.
HeartBeam (BEAT) is scheduled to host an earnings call on May 13, 2026, providing updates on key growth initiatives and product developments. The company's focus on cardiac care innovation and recent FDA clearances suggest positive prospects, but the stock's current somewhat-bullish sentiment indicates cautious optimism.
alphai scores every news story that mentions BEAT with an AI model for sentiment and relevance, and aggregates insider trades from HeartBeam, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001779372 0001779372 2026-07-31 2026-07-31 0001779372 us-gaap:CommonStockMember 2026-07-31 2026-07-31 0001779372 us-gaap:WarrantMember 2026-07-31 2026-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
2 min readHeartBeam Inc. (BEAT) said the U.S. Patent Office allowed a new patent covering acoustic sensing and thoracic impedance measurement for its cable-free ECG device. The company says the device can act as a digital stethoscope and monitor chest fluid buildup for heart failure management. BEAT shares were about $0.50, down 11.91%, near a 52-week low.
2 min readHeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001779372 0001779372 2026-06-18 2026-06-18 0001779372 us-gaap:CommonStockMember 2026-06-18 2026-06-18 0001779372 us-gaap:WarrantMember 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
2 min readHeartBeam, Inc. (BEAT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 ea029531801ex10-2.htm TRANSACTION BONUS AGREEMENT, DATED JUNE 15, 2026, BY AND BETWEEN HEARTBEAM, INC. AND BRANISLAV VAJDIC Exhibit 10.2 B Vajdic Performance Award 6.2026 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT
3 min readHeartBeam (NASDAQ: BEAT), a medical technology company, will host a conference call on May 13, 2026, to discuss its first-quarter results for 2026. The call will also provide updates on key growth initiatives, including its commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and AI programs. HeartBeam is focused on cardiac care innovation with its 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and 12-lead ECG synthesis software in December 2025.
4 min readHeartBeam President Robert Paul Eno purchased 12,500 shares of common stock at $0.80 per share on April 16, 2026, in connection with the company's 12.5 million-share public offering. This transaction increased his direct holdings to 36,742 shares, which includes 23,333 vested RSUs. The offering was priced on April 14, 2026, and closed on the same day as Eno's purchase.
2 min readHeartBeam, Inc. director Richard Ferrari purchased 62,500 shares of common stock at $0.80 per share in an open-market transaction directly connected to the company's underwritten public offering of 12,500,000 common shares. This purchase increases Ferrari's direct holdings to 291,636 shares, signaling his continued confidence in the company. The public offering, which priced on April 14, 2026, and closed on April 16, 2026, aims to raise capital for HeartBeam.
2 min readHeartBeam director Willem Elfrink purchased 187,500 shares of common stock at $0.80 per share on April 16, 2026, increasing his direct holdings to 538,667 shares. This transaction was part of HeartBeam's underwritten public offering, which closed on the same date. Titan Partners acted as the sole bookrunner for the offering.
2 min readAn entity associated with HeartBeam (NASDAQ: BEAT) director Michael R. Jaff, Open Book Healthcare, purchased 31,250 shares of common stock at $0.80 per share on April 16, 2026. This transaction was part of HeartBeam's underwritten public offering of 12,500,000 shares, which closed on the same day. Following the purchase, 31,250 shares are now indirectly held for Michael R. Jaff.
2 min readHeartBeam (NASDAQ: BEAT) announced its financial and operational results for Q4 and full-year 2025, highlighting progress in commercialization following FDA 510(k) clearance for its 12-lead ECG synthesis software. The company has initiated a limited market launch, secured its first commercial partnership, and begun enrolling patients in a pilot study for heart attack detection. Key developments also include a prototype extended-wear ECG patch and a strategic AI collaboration with the Icahn School of Medicine at Mount Sinai.
4 min read
